



(51) International Patent Classification:

A61K 38/50 (2006.01)

A61P 35/02 (2006.01)

A61K 45/06 (2006.01)

(21) International Application Number:

PCT/US2022/022635

(22) International Filing Date:

30 March 2022 (30.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/168,224

30 March 2021 (30.03.2021)

US

(71) Applicant: JAZZ PHARMACEUTICALS IRELAND

LTD. [IE/IE]; Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin, 4 (IE).

(72) Inventors: CHOI, Mi Rim; 6201 Enfield Ave., Encino,

California 91316 (US). LIN, Tong; 3101 Maddux Dr., Palo

Alto, California 94303 (US). SILVERMAN, Jeffrey; 1416

Columbus Ave., Burlingame, California 94010 (US).

(74) Agent: TALUKDER, Gargi et al.; ORRICK, HERRING-

TON & SUTCLIFFE LLP, 2050 MAIN STREET, SUITE

1100, Irvine, California 92614-8255 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: DOSING AND ADMINISTRATION OF RECOMBINANT L-ASPARAGINASE

(57) Abstract: The present invention provides compositions and methods for treating a disease treatable by asparagine depletion in a human subject comprising dosing a human subject with L-asparaginase.



WO 2022/212571 A1